Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.7 EUR | -0.45% | -4.39% | +2.17% |
Mar. 07 | Neurones: 11% growth in annual net income | CF |
Mar. 06 | Neurones S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With a 2023 P/E ratio at 21.57 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.17% | 1.17B | - | ||
-12.23% | 194B | A- | ||
+0.74% | 167B | B+ | ||
+2.19% | 155B | B- | ||
+4.34% | 101B | A- | ||
+7.04% | 76.69B | A- | ||
+19.09% | 72.08B | C- | ||
-7.30% | 71.48B | A | ||
-20.54% | 50.93B | C | ||
+0.53% | 48.89B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NRO Stock
- Ratings NEURONES